Supplementary Table S1 - S10 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Supplementary Table S1. Antibodies used for flow cytometry analyses. Supplementary Table S2. Selected marker genes to identify immune cell type in the transcriptomic NanoString analysis.Supplementary Table S3. Summary of sample inclusion in various immunoprofiling analyses.Supplementary Table S4. Treatment characteristics of the included PDAC patients (n = 30).Supplementary Table S5. Univariate Cox proportional hazards models for OS and PFS of the clinical covariates.Supplementary Table S6. Clinical and treatment characteristics of the PDAC patients included in the flow cytometry analysis.Supplementary Table S7. Pathway overrepresentation analyses of the transcriptomic NanoString analysis. Genes with significant overexpression (P < 0.01) in baseline samples compared to after 12 rintatolimod infusions are included.Supplementary Table S8. Univariate Cox proportional hazards models for OS and PFS of the NanoString immune cell counts.Supplementary Table S9. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients receiving ≤ and > median of 10 FOLFIRINOX cycles.Supplementary Table S10. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients who did receive and did not receive SBRT.